Kerstin sells BIIB 307.97: Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Mult ...
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.--(BUSINESS WIRE)-- Today Biogen Idec (NASDAQ:BIIB) and AbbVie (ABBV) (NYSE:ABBV) announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly ... ...
38 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home